Trends in CNS Drug Discovery

1. Auflage 2025
ISBN: 978-3-527-35280-7
Verlag: Wiley-VCH GmbH

Buch, Englisch, Band 2, 480 Seiten, Format (B × H): 175 mm x 247 mm, Gewicht: 1055 g

Reihe: Trends in Drug Discovery

Trends and challenges in one of the largest areas of contemporary drug development - presented by industry professionals with a track record of discovering new drugs and treatments.

Autoren/Hrsg.

Doller, Dario

Hodgetts, Kevin

Fischer, János

Klein, Christian

Childers, Wayne E.

Rotella, David P.

Weitere Mitwirkende

Fischer, János

Klein, Christian

Childers, Wayne E.

Rotella, David P.

Fachgebiete

• Naturwissenschaften Biowissenschaften Biowissenschaften Neurobiologie, Verhaltensbiologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Neurowissenschaften, Kognitionswissenschaft

Inhaltsverzeichnis

PART 1: CURRENT STATUS AND THERAPY OVERVIEW
Drug discovery in the Century of Biology
Academic vs. Industrial CNS drug discovery: An evolving relationship
The role of Venture Capital in drug discovery
Spin-off companies
The NIH role catalyzing the discovery of novel treatments
PART 2: KEY QUESTIONS FOR CONTEMPORARY CNS DRUG DISCOVERY
The end: defining CNS diseases (molecular vs phenotype)
Target selection in the treatment of CNS diseases
The use of animal models in brain drug research
Biomarkers in CNS drug discovery
PET imaging in CNS drug discovery
PART 3: PSYCHEDELIC-INSPRIRED DRUG DISCOVERY
Update on ketamine, esketamine, arketamine
Non-hallucinogenic antidepressants
Cannabinoids as therapeutics for brain disease
PART 4: UNION MAKES STRENGTH: COMBINING DRUGS TO PRODUCE NOVEL CNS THERAPEUTICS
Xanomeline-trospium for schizophrenia
Olanzapine-samidorphan
Dextromethorphan-bupropion
Levodopa prodrug
Apomorphine
PART 5: EMERGING CHEMICAL MODALITIES FOR BRAIN DISEASES
PROTACs in CNS drug discovery
Small molecule allosteric modulators
Progress using biologics drugs for CNS diseases (CGRP migraine, Anti-amyloid antibodies, MSA/PD and a-SYN antibodies)
Using mechanistic studies for CNS diseases
What is the best surrogate of brain penetration?
Brain cancer treatments (brain penetration of kinase inhibitor)
PART 6: EPILOGUE
Treating brain disease in the next decade
 

Über Autor(innen)

Dario Doller, PhD, has over 30 years of experience in pharmaceutical research, contributing to numerous clinical compounds and a marketed drug. He has authored over 100 articles and patents and is Chief Scientific Officer at Modulate Bio.

Kevin J. Hodgetts, PhD, is Associate Professor of Neurology at Harvard Medical School and Head of Medicinal Chemistry and Director of the Lab for Drug Discovery in Neuroscience (LDDN) at Brigham and Women’s Hospital.